Current Research Studies

Autism - JAKE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects with Autism Spectrum Disorder

What is the goal of this study?

Researchers at Seattle Children's are studying the effectiveness of a new study drug to improve symptoms of autism spectrum disorder.

Who can join the study?

This study may be a good fit for individuals who:

  • Are between 13 and 35 years old
  • Have been diagnosed with autism spectrum disorder (ASD)
  • Have an IQ of at least 60
  • Have a body mass index (BMI) between 18 and 35 or between the 5th and 95th percentile

What will happen if my child takes part in this study?

  • Participants will be in the study for up to 17 weeks and will be required to visit Seattle Children's every other week for a total of 8 study visits.
  • Participants will take either the study drug or placebo (a "sugar pill") during the study and get their blood drawn at 5 of the study visits
  • Study participants will be evaluated with a computer-based system that involves electronic assessments and biosensors, such as EEG, Eye Tracker and Actigraph, which measures activity and movement.

Study participants and their caregiver will both receive payment for completed study visits.


Who can I contact for more information?

To learn more, call 206-987-7917 or email the study coordinator.

Study Location(s):

Seattle Children's Autism Center

Principal Investigator:

Dr. Soo Kim